JAZZ - Jazz Pharmaceuticals PLC Stock Price, Fair Value and News

110.70USD-0.51 (-0.46%)Market Closed

Market Summary

USD110.70-0.51

Market Closed

-0.46%

JAZZ Alerts

1 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

JAZZ Stock Price

View Fullscreen

JAZZ RSI Chart

JAZZ Valuation

Market Cap

7.0B

Price/Earnings (Trailing)

21.1

Price/Sales (Trailing)

1.82

EV/EBITDA

17.59

Price/Free Cashflow

6.9

JAZZ Price/Sales (Trailing)

JAZZ Profitability

EBT Margin

6.28%

Return on Equity

8.95%

Return on Assets

2.92%

Free Cashflow Yield

14.49%

JAZZ Fundamentals

JAZZ Revenue

Revenue (TTM)

3.8B

Rev. Growth (Yr)

1.03%

Rev. Growth (Qtr)

-10.87%

JAZZ Earnings

Earnings (TTM)

330.8M

Earnings Growth (Yr)

-121.06%

Earnings Growth (Qtr)

-115.53%

Breaking Down JAZZ Revenue

Last 7 days

0.4%

Last 30 days

-3.8%

Last 90 days

-9.8%

Trailing 12 Months

-18.3%

How does JAZZ drawdown profile look like?

JAZZ Financial Health

Current Ratio

2.27

Debt/Equity

1.38

Debt/Cashflow

0.2

JAZZ Investor Care

Buy Backs (1Y)

1.51%

Diluted EPS (TTM)

4.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.8B	0	0	0
2023	3.7B	3.8B	3.8B	3.8B
2022	3.3B	3.5B	3.6B	3.7B
2021	2.4B	2.6B	2.9B	3.1B
2020	2.2B	2.2B	2.3B	2.4B
2019	2.0B	2.0B	2.1B	2.2B
2018	1.7B	1.8B	1.9B	1.9B
2017	1.5B	1.5B	1.6B	1.6B
2016	1.4B	1.4B	1.4B	1.5B
2015	1.2B	1.3B	1.3B	1.3B
2014	923.1M	1.0B	1.1B	1.2B
2013	679.7M	763.7M	820.4M	872.4M
2012	323.9M	383.6M	485.8M	586.0M
2011	272.3M	272.3M	272.3M	272.3M
2010	164.4M	200.4M	236.3M	272.3M
2009	0	0	0	128.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Jazz Pharmaceuticals PLC

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	patil neena m	sold	-548,250	109	-5,000	evp & chief legal officer
Apr 05, 2024	gala renee d	sold (taxes)	-200,005	115	-1,736	president & coo
Mar 07, 2024	carr patricia	sold	-206,821	116	-1,768	svp, chief accounting officer
Mar 06, 2024	carr patricia	sold	-231,628	119	-1,936	svp, chief accounting officer
Mar 05, 2024	patil neena m	sold (taxes)	-403,363	117	-3,432	evp & chief legal officer
Mar 05, 2024	cozadd bruce c	sold (taxes)	-2,636,900	117	-22,436	chairman & ceo
Mar 05, 2024	pearce samantha	sold (taxes)	-290,769	117	-2,474	svp, head of europe & internat
Mar 05, 2024	iannone robert	sold (taxes)	-504,674	117	-4,294	evp, global head of r&d
Mar 05, 2024	gala renee d	sold (taxes)	-425,694	117	-3,622	president & coo
Mar 01, 2024	carr patricia	acquired	-	-	2,987	svp, chief accounting officer

Which funds bought or sold JAZZ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Concurrent Investment Advisors, LLC	new	-	701,327	701,327	0.03%
May 07, 2024	TECTONIC ADVISORS LLC	added	20.07	58,087	388,957	0.03%
May 07, 2024	CHILTON CAPITAL MANAGEMENT LLC	unchanged	-	-15.00	723	-%
May 07, 2024	ClariVest Asset Management LLC	unchanged	-	-41.00	1,927	-%
May 07, 2024	M&T Bank Corp	reduced	-21.9	-125,719	406,848	-%
May 07, 2024	HIGHLAND CAPITAL MANAGEMENT, LLC	reduced	-1.19	-131,743	3,910,040	0.22%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-41.24	-3,806,490	5,155,660	-%
May 07, 2024	QRG CAPITAL MANAGEMENT, INC.	reduced	-10.43	-29,612	210,976	-%
May 07, 2024	OPPENHEIMER ASSET MANAGEMENT INC.	reduced	-11.09	-117,821	791,641	0.01%
May 07, 2024	Empowered Funds, LLC	sold off	-100	-2,283,130	-	-%

Are Funds Buying or Selling JAZZ?

Are funds buying JAZZ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JAZZ

No. of Funds

Unveiling Jazz Pharmaceuticals PLC's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	10.11%	6,363,748	SC 13G/A
Jan 24, 2024	blackrock inc.	11.2%	7,055,747	SC 13G/A
Sep 11, 2023	vanguard group inc	10.26%	6,479,474	SC 13G/A
Feb 09, 2023	vanguard group inc	9.61%	6,050,625	SC 13G/A
Jan 26, 2023	blackrock inc.	10.6%	6,652,382	SC 13G/A
Jan 20, 2023	blackrock inc.	10.6%	6,652,382	SC 13G
Jan 05, 2023	jpmorgan chase & co	4.6%	2,924,604	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Jan 28, 2022	blackrock inc.	10.5%	6,450,368	SC 13G/A
Jan 24, 2022	jpmorgan chase & co	5.2%	3,248,156	SC 13G

Recent SEC filings of Jazz Pharmaceuticals PLC

View All Filings

Date Filed	Form Type	Document
May 07, 2024	4	Insider Trading
May 03, 2024	144	Notice of Insider Sale Intent
May 02, 2024	10-Q	Quarterly Report
May 01, 2024	8-K	Current Report
Apr 26, 2024	10-K/A	Annual Report
Apr 09, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 07, 2024	144	Notice of Insider Sale Intent
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading

Peers (Alternatives to Jazz Pharmaceuticals PLC)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.13	14.32	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Jazz Pharmaceuticals PLC News

Latest updates

Jazz Pharmaceuticals PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-10.9%	902	1,012	972	957	893	972	941	933	814	897	838	752	608	666	601	562	535	582	538	534	508
Costs and Expenses	-6.0%	836	889	800	800	767	1,236	916	847	726	847	810	821	445	492	405	364	724	520	405	330	374
S&GA Expenses	-11.2%	352	396	308	341	298	383	358	366	309	398	364	429	261	247	207	191	208	214	179	176	168
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	97.00	80.00	62.00	60.00
EBITDA Margin	-8.8%	0.16*	0.17*	0.05*	0.01*	-0.01*	-0.02*	0.03*	0.02*	-0.02*	0.02*	0.05*	0.14*	-	-	-	-	-	-	-	-	-
Income Taxes	135.3%	12.00	-33.10	-47.20	-24.32	-15.30	-100	-43.00	-16.11	1.00	-12.46	-18.06	229	18.00	11.00	19.00	55.00	-51.29	-34.53	11.00	-78.65	29.00
Earnings Before Taxes	-102.6%	-1.60	62.00	100	82.00	55.00	-339	-60.13	21.00	6.00	-44.83	-67.63	-136	136	145	168	171	-209	41.00	114	184	115
EBT Margin	-19.2%	0.06*	0.08*	-0.03*	-0.07*	-0.09*	-0.10*	-0.02*	-0.02*	-0.07*	-0.04*	0.03*	0.12*	-	-	-	-	-	-	-	-	-
Net Income	-115.5%	-14.62	94.00	147	104	69.00	-240	-19.65	35.00	2.00	-35.35	-52.83	-363	122	133	148	115	-157	74.00	102	262	85.00
Net Income Margin	-20.4%	0.09*	0.11*	0.02*	-0.02*	-0.04*	-0.06*	-0.01*	-0.01*	-0.14*	-0.11*	-0.06*	0.02*	-	-	-	-	-	-	-	-	-
Free Cashflow	65.6%	260	157	303	291	317	333	423	291	197	168	266	35.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.6%	11,327	11,393	11,204	11,261	11,047	10,835	10,385	11,200	11,769	12,299	12,478	13,213	6,756	6,536	6,292	6,067	5,215	5,539	5,528	5,489	5,280
Current Assets	3.0%	3,540	3,435	3,246	3,010	2,785	2,606	2,572	2,591	2,501	2,611	2,628	2,954	3,167	2,840	2,556	2,302	1,518	1,630	1,521	1,370	1,306
Cash Equivalents	-4.2%	1,443	1,506	1,336	1,282	1,168	881	839	711	491	591	672	891	2,098	1,058	742	786	702	637	795	638	547
Inventory	-3.3%	577	597	612	657	675	714	728	862	985	1,073	1,138	1,251	115	95.00	91.00	93.00	86.00	79.00	71.00	69.00	61.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	124	128	128	128	130	132	129	127	113
Goodwill	-0.8%	1,739	1,753	1,705	1,743	1,723	1,693	1,593	1,688	1,782	1,828	1,850	1,888	938	958	937	918	909	920	907	925	920
Current Liabilities	1.7%	1,562	1,537	1,573	945	909	933	813	705	737	809	735	881	752	654	642	410	396	364	390	369	414
Long Term Debt	-0.1%	5,105	5,108	5,111	5,687	5,690	5,693	5,696	5,990	5,993	6,019	6,247	6,489	1,853	1,849	1,844	2,070	1,577	1,574	1,571	1,568	1,565
LT Debt, Current	0.1%	605	605	605	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	249	249	246	244	33.00	33.00	33.00	33.00	33.00	33.00
LT Debt, Non Current	-100.0%	-	5,108	5,111	5,687	5,690	5,693	5,696	5,990	5,993	6,019	6,247	6,489	1,853	1,849	1,844	2,070	1,577	1,574	1,571	1,568	1,565
Shareholder's Equity	-1.1%	3,696	3,737	3,489	3,526	3,335	3,086	2,745	3,201	3,608	3,965	3,938	4,131	3,798	3,660	3,377	3,142	2,809	3,111	3,054	2,983	2,730
Retained Earnings	-1.7%	864	879	884	812	803	734	974	994	959	830	866	918	1,282	1,160	1,026	878	771	1,068	1,104	1,022	820
Additional Paid-In Capital	0.4%	3,714	3,700	3,640	3,580	3,512	3,477	3,388	3,312	3,239	3,535	3,470	3,403	2,695	2,634	2,538	2,499	2,294	2,266	2,209	2,171	2,131
Shares Outstanding	1.3%	63.00	62.00	64.00	64.00	63.00	63.00	63.00	62.00	62.00	60.00	59.00	59.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	7,660	-	-	-	9,527	-	-	-	10,591	-	-	-	5,958	-	-	-	7,870	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	59.7%	267,229	167,339	307,195	296,765	320,708	341,971	417,991	303,036	208,979	177,755	274,060	41,695	284,997	186,271	257,889	182,519	272,969	87,798	337,503	148,847	202,253
Share Based Compensation	16.1%	61,441	52,941	56,115	61,433	56,352	61,558	56,681	53,687	50,070	53,119	53,239	48,163	34,485	31,384	30,356	30,604	28,654	25,937	28,785	28,289	27,552
Cashflow From Investing	-367.1%	-271,904	101,798	-174,299	-85,739	-4,822	-324,378	4,602	-89,162	-37,292	-10,092	-26,813	-5,912,370	737,132	73,219	-279,644	-741,165	-60,080	-159,053	-159,661	-2,638	166,052
Cashflow From Financing	43.6%	-56,552	-100,306	-78,493	-96,667	-29,788	19,596	-289,053	10,777	-270,811	-246,609	-465,181	4,664,036	18,276	55,878	-22,656	642,534	-147,683	-87,780	-19,463	-56,153	-130,349
Buy Backs	-100.0%	-	99,795	74,371	95,594	-	-	-	54.00	-	-	-	-	-	-	-	7,484	139,053	110,335	19,997	59,869	111,249

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

JAZZ Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 901,983	$ 892,812
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	95,487	128,644
Selling, general and administrative	351,712	297,917
Research and development	222,847	189,410
Intangible asset amortization	155,730	149,786
Acquired in-process research and development	10,000	1,000
Total operating expenses	835,776	766,757
Income from operations	66,207	126,055
Interest expense, net	(66,116)	(74,147)
Foreign exchange gain (loss)	(1,693)	3,193
Income (loss) before income tax expense (benefit) and equity in loss of investees	(1,602)	55,101
Income tax expense (benefit)	11,669	(15,324)
Equity in loss of investees	1,347	1,005
Net income (loss)	$ (14,618)	$ 69,420
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ (0.23)	$ 1.09
Diluted (in dollars per share)	$ (0.23)	$ 1.04
Weighted-average ordinary shares used in per share calculations - basic (in shares)	62,537	63,494
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	62,537	73,771
Product sales, net
Revenues:
Total revenues	$ 842,102	$ 884,219
Royalties and contract revenues
Revenues:
Total revenues	$ 59,881	$ 8,593

JAZZ Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,443,385	$ 1,506,310
Investments	375,000	120,000
Accounts receivable, net of allowances	707,095	705,794
Inventories	577,321	597,039
Prepaid expenses	122,562	185,476
Other current assets	314,535	320,809
Total current assets	3,539,898	3,435,428
Property, plant and equipment, net	166,236	169,646
Operating lease assets	61,637	65,340
Intangible assets, net	5,235,496	5,418,039
Goodwill	1,739,495	1,753,130
Deferred tax assets, net	507,749	477,834
Deferred financing costs	5,784	6,478
Other non-current assets	70,780	67,464
Total assets	11,327,075	11,393,359
Current liabilities:
Accounts payable	80,976	102,750
Accrued liabilities	826,530	793,914
Current portion of long-term debt	605,375	604,954
Income taxes payable	49,325	35,074
Total current liabilities	1,562,206	1,536,692
Long-term debt, less current portion	5,105,111	5,107,988
Operating lease liabilities, less current portion	56,158	59,225
Deferred tax liabilities, net	809,714	847,706
Other non-current liabilities	97,425	104,751
Commitments and contingencies (Note 9)
Shareholders’ equity:
Ordinary shares	6	6
Non-voting euro deferred shares	55	55
Capital redemption reserve	473	473
Additional paid-in capital	3,714,283	3,699,954
Accumulated other comprehensive loss	(882,394)	(842,147)
Retained earnings	864,038	878,656
Total shareholders’ equity	3,696,461	3,736,997
Total liabilities and shareholders’ equity	$ 11,327,075	$ 11,393,359

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

CEO	Mr. Bruce C. Cozadd
WEBSITE	jazzpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	2800

Jazz Pharmaceuticals PLC Frequently Asked Questions

What is the ticker symbol for Jazz Pharmaceuticals PLC? What does JAZZ stand for in stocks?

JAZZ is the stock ticker symbol of Jazz Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jazz Pharmaceuticals PLC (JAZZ)?

As of Wed May 08 2024, market cap of Jazz Pharmaceuticals PLC is 6.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JAZZ stock?

You can check JAZZ's fair value in chart for subscribers.

What is the fair value of JAZZ stock?

You can check JAZZ's fair value in chart for subscribers. The fair value of Jazz Pharmaceuticals PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Jazz Pharmaceuticals PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JAZZ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Jazz Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether JAZZ is over valued or under valued. Whether Jazz Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Jazz Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAZZ.

What is Jazz Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, JAZZ's PE ratio (Price to Earnings) is 21.1 and Price to Sales (PS) ratio is 1.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAZZ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Jazz Pharmaceuticals PLC's stock?

In the past 10 years, Jazz Pharmaceuticals PLC has provided -0.016 (multiply by 100 for percentage) rate of return.